DRMAW (Dermata Therapeutics, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by DRMAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Kathleen D. Scott | Director | Sell | — | — |
| 2026-03-17 | Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | Buy | — | — |
| 2026-01-06 | WENDELL WIERENGA | Director | A | — | — |
| 2026-01-06 | MARY FISHER | Director | A | — | — |
| 2026-01-06 | Andrew Seth Sandler | Director | A | — | — |
| 2026-01-06 | Kathleen D. Scott | Director | A | — | — |
| 2026-01-06 | Brittany Bradrick | Director | A | — | — |
| 2026-01-06 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2026-01-06 | DAVID F HALE | Director | A | — | — |
| 2026-01-06 | GERALD T PROEHL | President, CEO and Chairman | A | — | — |
| 2026-01-06 | Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | A | — | — |
| 2026-01-06 | Steven J Mento | Director | A | — | — |
| 2026-01-06 | Christopher J. Nardo | Senior VP, CDO | A | — | — |
| 2025-12-29 | GERALD T PROEHL | PRESIDENT, CHAIRMAN, CEO | A | — | — |
| 2025-12-29 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2025-01-23 | MARY FISHER | Director | A | — | — |
| 2025-01-23 | DAVID F HALE | Director | A | — | — |
| 2025-01-23 | GERALD T PROEHL | President, CEO and Chairman | A | — | — |
| 2025-01-23 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2025-01-14 | Kathleen D. Scott | Director | A | — | — |
| 2025-01-14 | DAVID F HALE | Director | A | — | — |
| 2025-01-14 | MARY FISHER | Director | A | — | — |
| 2025-01-14 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2025-01-14 | Christopher J. Nardo | Senior VP, CDO | A | — | — |
| 2025-01-14 | GERALD T PROEHL | President, CEO and Chairman | A | — | — |
| 2025-01-14 | Andrew Seth Sandler | Director | A | — | — |
| 2025-01-14 | WENDELL WIERENGA | Director | A | — | — |
| 2025-01-14 | Brittany Bradrick | Director | A | — | — |
| 2025-01-14 | Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | A | — | — |
| 2025-01-14 | Steven J Mento | Director | A | — | — |
| 2024-01-05 | Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | A | — | — |
| 2024-01-05 | GERALD T PROEHL | President, CEO and Chairman | A | — | — |
| 2024-01-05 | Christopher J. Nardo | Senior VP, CDO | A | — | — |
| 2024-01-05 | Andrew Seth Sandler | Director | A | — | — |
| 2024-01-05 | Kathleen D. Scott | Director | A | — | — |
| 2024-01-05 | DAVID F HALE | Director | A | — | — |
| 2024-01-05 | MARY FISHER | Director | A | — | — |
| 2024-01-05 | WENDELL WIERENGA | Director | A | — | — |
| 2024-01-05 | Steven J Mento | Director | A | — | — |
| 2024-01-05 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2024-01-05 | Brittany Bradrick | Director | A | — | — |
| 2023-01-05 | Kyri K. Van Hoose | SVP, CFO | A | — | — |
| 2023-01-05 | Christopher J. Nardo | Senior VP, CDO | A | — | — |
| 2023-01-05 | Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | A | — | — |
| 2022-10-07 | MARY FISHER | Director | A | — | — |
| 2022-10-07 | Brittany Bradrick | Director | A | — | — |
| 2022-10-07 | WENDELL WIERENGA | Director | A | — | — |
| 2022-10-07 | Kathleen D. Scott | Director | A | — | — |
| 2022-10-07 | Andrew Seth Sandler | Director | A | — | — |
| 2022-10-07 | DAVID F HALE | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,390,415 | — |
| — | Director | 196,946 | — |
| — | SVP, CFO | 130,423 | — |
| — | Director | 62,398 | — |
| — | Senior VP, CDO | 27,560 | — |
| — | Director | 24,184 | — |
| — | Director | 23,443 | — |
| — | Chief Financial Officer | 14,337 | — |
| — | SVP, Regulatory Affairs | 1,046 | — |
| — | Director | 364 | — |
| — | President, CEO and Chairman | 31 | — |
| — | Director | 1 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DRMAW quote page; the site-wide leaderboard is on the insider transactions hub.